Candel Therapeutics, Inc. (NASDAQ:CADL) was the recipient of a significant decrease in short interest in September. As of September 30th, there was short interest totalling 90,600 shares, a decrease of 34.4% from the September 15th total of 138,200 shares. Currently, 0.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 179,500 shares, the days-to-cover ratio is currently 0.5 days.
Shares of CADL stock traded down $0.03 during trading hours on Monday, hitting $9.80. 111 shares of the company’s stock were exchanged, compared to its average volume of 131,979. Candel Therapeutics has a 12-month low of $5.51 and a 12-month high of $14.78. The stock has a 50 day simple moving average of $8.88.
Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings results on Wednesday, September 8th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.05. The business had revenue of $0.03 million for the quarter. As a group, equities analysts forecast that Candel Therapeutics will post -1.22 EPS for the current fiscal year.
About Candel Therapeutics
Candel Therapeutics Inc is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company’s product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc is based in NEEDHAM, Mass.
Further Reading: How is net asset value different from market price?
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.